Feb 14, 2019 - Incyte Corporation (NASDAQ:INCY) Q4 2018 Results Conference Call February 14, 2019 08:00 AM ET Company Participants Mike Booth - VP, IR Hervé Hoppenot - President and CEO Barry Flannelly - EVP, Genera
Feb 14, 2019 - INCY earnings call for the period ending December 31, 2018.
Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Feb 11, 2019 - Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
Feb 11, 2019 - Overpriced toxic stocks are generally susceptible to external shocks and loaded with huge amount of debt.
Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Jan 25, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
Jan 24, 2019 - Gabelli & Co issues rating change for INCY
Jan 23, 2019 - A low key week for the biotech sector with regular drug approvals and pipeline updates.